Showing 7851-7860 of 9496 results for "".
- The HydraFacial Company And Circadia Expand Partner Boosters Globallyhttps://practicaldermatology.com/news/the-hydrafacial-company-and-circadia-expand-partner-boosters-globally/2460579/The HydraFacial Company is extending their partnership with Circadia to offer the Chrono-Peptide Booster and ProTec Plus Booster to HydraFacial providers in more than 40 countries. "The Circadia boosters for HydraFacial are already loved by providers and consume
- Beiersdorf Inc. Observes 10 Years of dermMentors Residents of Distinctionhttps://practicaldermatology.com/news/beiersdorf-inc-observes-10-years-of-dermmentors-residents-of-distinction/2460577/As part of the dermMentors™ Resident of Distinction Award™, Beiersdorf Inc. sponsored five top dermatology residents to attend the 16th Annual Coastal Dermatology Symposium, held in a Virtual Format for 2020. The 2020 Residents of Distinction are Shaundra Eichsta
- Soligenix's Phase 3 FLASH Study Continues to Demonstrate Positive Benefits of SGX301 in Cutaneous T-Cell Lymphoma Patientshttps://practicaldermatology.com/news/soligenixs-phase-3-flash-study-continues-to-demonstrate-positive-benefits-of-sgx301-in-cutaneous-t-cell-lymphoma-patients/2460576/Continued optional treatment with Soligenix, Inc.’s SGX301 (synthetic hypericin) demonstrates positive benefits in patients with cutaneous T-Cell lymphoma Nearly half of all patients in Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin) trial conti
- Coping with COVID: Most Psoriasis Patients Taking Immunosuppressants Survive COVID-19https://practicaldermatology.com/news/coping-with-covid-most-pso-patients-taking-immunosuppressants-survive-covid-19/2460573/Patients with psoriasis who are taking drugs that affect their immune system have high rates of survival from COVID-19, according to the first findings from a global registry of psoriasis and COVID-19 patients. The initial findings from the PsoProtect registry, which appear in the
- SOC, VisualDX, and NEJM Group Launch Webinar Series to Explore Issues in Skin Colorhttps://practicaldermatology.com/news/soc-visualdx-and-nejm-group-launch-webinar-series-to-explore-issues-in-skin-color/2460570/“The Impact of Skin Color and Ethnicity on Clinical Diagnosis and Research,” a new webinar series presented by the Skin of Color Society, NEJM Group, and VisualDx launches this month to call attention to health disparities and structural racism in medicine.
- Data Confirm Efficacy, Safety of Nutrafol for Menopausal Womenhttps://practicaldermatology.com/news/data-confirm-efficacy-safety-of-nutrafol-for-menopausal-women/2460563/Administration of Nutrafol’s Women’s Balance formulationis safe and effective in improving hair growth and quality in women going through menopausal transition, according to new data. Presented in a poster presentation at the Annual Meeting of the American Society for D
- Call for Entries: Hacking Dermatology 2020 Innovation Challenge to Focus on Dermatologic Challenges in Skin of Colorhttps://practicaldermatology.com/news/call-for-entries-hacking-dermatology-2020-innovation-challenge-to-focus-on-dermatologic-challenges-in-skin-of-color/2460562/Applications are now being accepted for
- Kerecis Scores DoD Grant to Develop, Test New Fish-skin Wound Treatment for Soldiershttps://practicaldermatology.com/news/kerecis-scores-dod-grant-to-develop-test-new-fish-skin-wound-treatment-for-soldiers/2460561/The U.S. Department of Defense (DoD) awarded a grant of almost $600,000 to Kerecis to test the company’s fish-skin technology to better stabilize battlefield wounds and provide a bacterial barrier for them during evacuation. The grant money will be disbursed to Kerecis over
- Third RAD Conference Goes Virtual in Decemberhttps://practicaldermatology.com/news/third-rad-conference-goes-virtual-in-december/2460555/With a virtual format, the Third Revolutionizing Atopic Dermatitis (RAD) Conference is slated for December 13-14, 2020. Described by organizers as the first and only global, multidisciplinary conference dedicated to the discussion of evaluation and treatment options for atopi
- Brickell Biotech Initiates Phase 3 Trial of Sofpironium Bromide Gel for Hyperhidrosishttps://practicaldermatology.com/news/brickell-biotech-initiates-phase-3-trial-of-sofpironium-bromide-gel-for-hyperhidrosis/2460554/Brickell Biotech, Inc. has initiated its first pivotal US Phase 3 clinical study evaluating sofpironium bromide gel, 15% as a potential treatment for primary axillary hyperhidrosis (“Cardigan I Study”). “This continues to be an exciting time for Brickell, with initiati